Pasithea Therapeutics Opens New Trial Site for PAS-004

An announcement from Pasithea Therapeutics Corp ( (KTTA) ) is now available.

On November 4, 2025, Pasithea Therapeutics Corp announced the activation of a new U.S. clinical trial site at the University of Alabama at Birmingham for its ongoing Phase 1/1b study of PAS-004 in adult patients with neurofibromatosis type 1. This trial aims to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of PAS-004, with immediate enrollment expected at the UAB site. Additionally, the company will serve as the Platinum Sponsor for the 2025 NF Caregivers Symposium, highlighting its commitment to the NF1 community. This development underscores Pasithea’s strategic efforts to advance PAS-004 through clinical development and strengthen its position in the biotechnology industry.

More about Pasithea Therapeutics Corp

Pasithea Therapeutics Corp is a clinical-stage biotechnology company focusing on the research and development of PAS-004, a next-generation macrocyclic MEK inhibitor aimed at treating RASopathies, MAPK pathway-driven tumors, and other diseases. The company is currently conducting Phase 1 clinical trials for PAS-004 in advanced cancer patients and a Phase 1/1b trial in adult patients with neurofibromatosis type 1-associated plexiform neurofibromas.

Average Trading Volume: 120,580

Technical Sentiment Signal: Sell

Current Market Cap: $6.07M

For a thorough assessment of KTTA stock, go to TipRanks’ Stock Analysis page.